TARS · Tarsus Pharmaceuticals, Inc.

The thesis

Tarsus Pharmaceuticals is a one-product company whose case rests on XDEMVY, its treatment for eyelid mite infestation (Demodex blepharitis), growing fast enough to fund the Alkeus eye-care pipeline. The third-quarter 2026 report, expected around 5 November 2026, settles it: sales need to beat the second quarter's $173.9 million and the $685–705 million full-year guidance needs to stand.

The shares closed at $70.76 on 27 October 2026, 22.1% below the 52-week high of $90.78 and below the $72.29 close of 14 October 2026. Adjusted daily closes show a 3-month gain of 18.8%, and the 14-day relative strength index (RSI, a 0–100 momentum gauge) reads 44.1. No new sales figure has appeared since the 6 August 2026 report, so the drift lower since the last note is a price move and the business evidence is unchanged.

The narrative is maturing: the XDEMVY launch is well known, three firms published bullish targets between 8 September 2026 and 24 September 2026, and company news since then has been conference abstracts and share-registration filings. Sales data arrives with the third-quarter report.

Bullish and bearish views on Tarsus Pharmaceuticals, Inc.

The bull case on Tarsus Pharmaceuticals, Inc. (TARS), in brief: Sales growth led to a guidance raise. The bear case: Spending is growing faster than sales.

Bull case

• Sales growth led to a guidance raise. Tarsus reported first-quarter 2026 XDEMVY net product sales of $145.4 million, up 85% year over year. On 6 August 2026 it reported second-quarter sales of $173.9 million, up more than 69%, and raised 2026 guidance from $670–700 million to $685–705 million. Q2 2026 release
• Analyst targets sit far above the share price. According to Benzinga, Jefferies raised its target to $105 on 8 September 2026, Barclays reinstated at Overweight with $110 on 16 September 2026, and Goldman Sachs reinstated at Buy with $116 on 24 September 2026. The $70.76 close on 27 October 2026 is below all three.
• The acquired retina drug has peer-reviewed data. JAMA Ophthalmology published the TEASE-1 results on 3 September 2026. In the 50-patient Stargardt disease trial, gildeuretinol cut the growth rate of retinal lesions by 21.6% compared with untreated patients.
• Cash cover is meaningful. Tarsus held $449.7 million in cash, cash equivalents and marketable securities at 30 June 2026, before the roughly $125 million equity financing announced on 6 August 2026.

Bear case

• Spending is growing faster than sales. Second-quarter 2026 selling, general and administrative expense was $150.7 million, up from $103.0 million a year earlier. Research and development expense was $31.0 million, up from $15.6 million. The net loss was $18.6 million.
• Share supply keeps arriving. A prospectus filed 13 October 2026 covers resale of up to 2.91 million shares by selling stockholders. Earlier, $180 million of the $450 million Alkeus upfront payment was paid in Tarsus stock.
• The pipeline pays off late. The 6 August 2026 release guides topline data for TP-04 (ocular rosacea) and TP-05 (Lyme disease) to the first half of 2027 and IRX-101 Phase 3 results to 2028. Gildeuretinol's registrational NORTHSTAR readout is guided to 2029. XDEMVY sales carry the valuation until then.
• Every dollar of revenue is one product. XDEMVY made up all $173.9 million of second-quarter net product sales.

Price setup

Adjusted daily closes put the shares at $70.76 on 27 October 2026. That is 22.1% below the 52-week high of $90.78 and below the $74.40 sale price cited in the 12 October 2026 resale prospectus. The 14 October 2026 close was $72.29, so the shares have given up a further 1.53 dollars since the last note.

The RSI of 44.1 on 27 October 2026 is below the midpoint of its range and above the 40.8 reading of 14 October 2026. The shares are neither stretched above a rising moving average nor oversold.

Crowding evidence is limited. The earnings date is close, an estimated 3 November to 10 November 2026 window. Resale registrations filed in October cover stock that selling stockholders can sell. SEC Form 4 insider transactions are not part of the evidence reviewed for this note, so no insider-selling reading is drawn.

The $65 level, a daily close below which breaks the price case, sits under both recent closes.

Catalysts, next 30 days

• ~5 November 2026, est.: third-quarter 2026 financial report. Tarsus has not confirmed the date. Earnings Whispers lists 10 November 2026 after the close, The Right Trader projects 3 November 2026, and the company reported the third quarter of 2025 on 4 November 2025. The report shows whether XDEMVY sales beat $173.9 million and whether the $685–705 million guidance holds.
• First half of 2027: TP-04 and TP-05 topline data. This is outside the 30-day window. It matters because the next pipeline evidence arrives only then.

What would change the view

The case breaks if third-quarter 2026 XDEMVY net product sales come in at or below the second quarter's $173.9 million, or if Tarsus cuts either end of the $685–705 million 2026 guidance. Either result would show the launch slowing while SG&A of $150.7 million per quarter and R&D of $31.0 million keep the company loss-making.

A new equity offering or a stock-funded acquisition before the 2027 TP-04 and TP-05 readouts would add to share supply already registered on 13 October 2026. A NORTHSTAR miss, a discontinuation or a readout date moved beyond 2029 would weaken the pipeline premise.

On price, a daily close below $65 would put the shares well under the recent range and the 27 October 2026 close of $70.76. A sales beat with guidance raised would instead strengthen the commercial case and test the three September targets.

What it trades with

No investment theme currently carries this name, and no measured correlation figures are available for this note. XDEMVY sales are specific to Tarsus, so the shares are likely to move on prescription trends and the third-quarter report more than on sector data. Small and mid-cap commercial-stage biotech shares generally react to financing conditions, which makes the October resale registrations a relevant sector link.